Eye Clinic, Department of Medical Surgical Specialties, University of Catania, Catania, Italy.
Department of Clinical and Molecular Biomedicine, Section of Pharmacology and Biochemistry, University of Catania, Catania, Italy.
Eye (Lond). 2014 Jan;28(1):53-7. doi: 10.1038/eye.2013.232. Epub 2013 Oct 25.
To investigate the success (glaucoma control) of latanoprost therapy of primary congenital glaucoma (PCG) and factors affecting the long-term outcome.
Patients with PCG treated with latanoprost were re-examined. At study visit and from clinical charts, we evaluated: intraocular pressure, length of glaucoma control with latanoprost, need of further medication or glaucoma surgery, systemic and topical side effects. Multivariate analysis was used to test factors related to the final outcome of the treatment.
Eighty-one eyes of 44 patients with PCG, and 42 eyes of 29 patients with previous glaucoma surgery, had received latanoprost therapy. In the first group, a success (glaucoma control by latanoprost therapy) was found in 24 eyes (29.6%), whereas 57 eyes (70.4%) had received surgery (45 eyes (55.6%) in the first year); among the eyes with previous surgery, a success was found in 12 eyes (28.6%), 13 eyes (31%) required an additional therapy, and 17 eyes (40.5%) had received further glaucoma surgery. No patient discontinued the treatment because of side effects. Factors related to the failure of the latanoprost treatment were: the high score of severity of glaucoma (P=0.014) and low age at PCG presentation (P=0.042).
Long-term treatment with latanoprost is effective in about 30% of the eyes; factors related to failure were severe glaucomatous alterations, and young age at PCG presentation.
研究原发性先天性青光眼（PCG）患者应用拉坦前列素治疗的成功率（青光眼控制）及其影响长期疗效的因素。
对应用拉坦前列素治疗的 PCG 患者进行复查。在研究访问和临床病历中，我们评估了：眼内压、拉坦前列素控制青光眼的时间、是否需要进一步药物或青光眼手术、全身和局部副作用。采用多变量分析来测试与治疗最终结果相关的因素。
44 例 PCG 患者的 81 只眼和 42 例曾接受过青光眼手术的患者的 42 只眼接受了拉坦前列素治疗。在第一组中，24 只眼（29.6%）通过拉坦前列素治疗成功（青光眼得到控制），而 57 只眼（70.4%）接受了手术（45 只眼（55.6%）在第一年）；在既往手术的眼中，12 只眼（28.6%）成功，13 只眼（31%）需要额外治疗，17 只眼（40.5%）接受了进一步的青光眼手术。没有患者因副作用而停止治疗。与拉坦前列素治疗失败相关的因素是：青光眼严重程度评分高（P=0.014）和 PCG 发病时年龄低（P=0.042）。
长期应用拉坦前列素治疗对约 30%的眼有效；失败的相关因素是严重的青光眼改变和 PCG 发病时的低龄。
